Emerging Pharmacologic Therapies for Heart Failure With Reduced Ejection Fraction.

Autor:	Chaudhary AG; Cardiovascular Diseases Department, King Faisal Specialist Hospital and Research Centre (Gen. Org.), Jeddah, Saudi Arabia., Alreefi FM; Cardiovascular Diseases Department, King Faisal Specialist Hospital and Research Centre (Gen. Org.), Jeddah, Saudi Arabia., Aziz MA; Cardiovascular Diseases Department, King Faisal Specialist Hospital and Research Centre (Gen. Org.), Jeddah, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	CJC open [CJC Open] 2021 Feb 01; Vol. 3 (5), pp. 646-657. Date of Electronic Publication: 2021 Feb 01 (Print Publication: 2021).
DOI:	10.1016/j.cjco.2021.01.006
Abstrakt:	The global burden of heart failure has reached epidemic proportions with tremendous health and economic consequences. Sodium glucose cotransporter 2 inhibitors, vericiguat, and omecamtiv mecarbil are novel agents that promise to blunt the high residual risk of heart failure with reduced ejection fraction. We review the vast knowledge base that has rapidly materialized for these agents and is poised to shape the current and future trends and recommendations in heart failure pharmacotherapy. (© 2021 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu